GlassScriptPhysician profile
Maqbool A Halepota
NPI 1558384966
$4,176.86
in general payments reported to CMS, 2019-2025
46 companies · $686 in 2025
The $686 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $273 · 2021: $117 · 2022: $714 · 2023: $620 · 2024: $1,087 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.40 |
| Education | $132.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $489.11 | 2019-2025 | |
| Abbvie INC. | $425.80 | 2019-2025 | |
| Amgen INC. | $291.98 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Seagen INC. | $276.06 | 2020-2025 | Padcev |
| Merck Sharp & Dohme LLC | $197.10 | 2019-2024 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $184.11 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Sumitomo Pharma America, INC. | $159.98 | 2024 | Orgovyx |
| Genentech USA, INC. | $155.29 | 2019-2025 | Polivy, Columvi, Lunsumio |
| Servier Pharmaceuticals LLC | $138.11 | 2022-2025 | |
| Gilead Sciences, INC. | $129.31 | 2019-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.06 | 2019-2020 | |
| Taiho Oncology, INC. | $120.05 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $111.14 | 2021-2025 | Imfinzi |
| Janssen Biotech, INC. | $109.41 | 2019-2024 | Carvykti |
| Array Biopharma INC | $102.36 | 2020-2025 | Xalkori, Lorbrena, Braftovi |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maqbool Halepota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.